ImaginAB and Eli Lilly announced a pre-clinical collaboration to use ImaginAb’s immune imaging agent IAB22M2C to study new T-cell therapies cancer. Continue reading
![](https://blogs.shu.edu/cancer/files/2014/07/cancerBiology180x110.jpg)
ImaginAB and Eli Lilly announced a pre-clinical collaboration to use ImaginAb’s immune imaging agent IAB22M2C to study new T-cell therapies cancer. Continue reading
Why elephants do not get cancer is a famous conundrum that was posed by epidemiologist Richard Peto of the University of Oxford, UK, in the 1970’s. Peto noted that, in general, there is little relationship between cancer rates and the body size or age of animals. Continue reading
DNAtrix and Merck announced a collaboration to combine oncolytic virus therapy and PD-1 inhibition – the two companies will collaborate in phase II clinical trials on a therapy to treat glioblastoma, an especially deadly cancer for which there is no cure. Continue reading
Celgene and Nurix entered into a collaboration to develop small molecule treatments for cancer that target the ubiquitin proteasome system (UPS). Continue reading
Liquid biopsy is the use of blood to diagnose cancer. Pathway Genomics launched its CancerIntercept test that screens for multiple cancers. Continue reading
Immatics, a German biotechnology company has established a subsidiary in Houston, TX to collaborate with MD Anderson on overcoming some of the limitations to the adoptive T cell therapies now in the immuno-oncology pipeline. The collaboration covers the use of cytokine IL-21 to expand high-quality T cell batches, particularly those generated by CAR-T (chimeric antigen receptor T-cell) and related approaches. Continue reading
The US Food and Drug Administration (FDA) has approved Varubi (rolapitant) (Tesaro) as part of a combination of drugs to prevent nausea and vomiting caused by certain types of cancer chemotherapy. More specifically, it was approved to prevent delayed phase chemotherapy-induced nausea and vomiting (CINV). Continue reading
Question: How do you turn aggressive breast, lung, and bladder cancer cells back into benign cells?
Answer: microRNAi’s. Continue reading
Janssen Biotech acquired a worldwide license to Alligator Bioscience’s Phase I immunotherapy ADC-1013, an agonistic monoclonal antibody that targets CD40, an immuno-stimulatory receptor found on antigen-presenting cells, which can spur an increase in T cells attacking a tumor. Continue reading
Therakos’ Cellex extracorporeal photopheresis system is used to administer autologous immune cell therapy for the treatment of cutaneous T-cell lymphoma (CTCL), the two most common forms of which include mycosis fungoides (up to 20,000 case per year in the US) and Sézary Syndrome, which is an aggressive form of the disease. in total, CTCL’s account for less than 4% of all non-Hodgkins lymphomas. Continue reading